Menu
Not yet recruiting NCT06961877

Skills for Talking About Cannabis for Families of Young Adults With Psychosis

No phase Interventional Caregiver Burden Cannabis Use Expressed Emotion Communications Skills

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Cannabis Conversation Skills for Families (CCSF).
Who it may be relevant to
Registry conditions: Caregiver Burden, Cannabis Use, Expressed Emotion, Communications Skills. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Talking About Cannabis: Developing an Intervention for Family Members of Young Adults With FEP to Support Reduced Cannabis Use

Overview

The objectives of this research is to (1) create a family intervention and provider manual to train family members of young people with psychosis (YP-P) who are heavy cannabis users new communication skills to motivate change in the YP-P's cannabis use, (2) pre-test the intervention with 10 family member participants and adapt the intervention based on their recommendations, and (3) evaluate the feasibility and acceptability of the intervention in a randomized pilot trial (n=40). The investigators anticipate that the intervention will improve family participants' communication skills, decrease expressed emotion and caregiver burden. The investigators anticipate that improvements in communication skills, expressed emotion and caregiver burden will lead to decreases in the cannabis use of their YP-P.

Detailed description

The objectives of this research will be implemented in two phases. Phase II will develop a family intervention informed by a Stakeholder Advisory Board and pre-test the intervention will be adapted with 10 family member participants. The intervention based on recommendations in phase 1. The investigators anticipate that the intervention will improve family participants' communication skills, decrease expressed emotion and caregiver burden. The investigators anticipate that improvements in communication skills, expressed emotion and caregiver burden will lead to decreases in the cannabis use of their YP-P.

Phase 2 will evaluate the acceptability, feasibility, and preliminary effect sizes of the intervention in a pilot randomized controlled trial comparing it to treatment as usual (TAU) with 40 family participants. This pilot test is consistent with the stated purpose of Stage 1B of the NIH Stage Model for behavioral intervention development and the R34 mechanism of "providing resources for evaluating the feasibility, tolerability, acceptability and safety and preliminary effectiveness of approaches to improve mental health/functional outcomes". The purpose of this pilot study is to develop and test the feasibility and acceptability of the intervention protocol, study procedures, and recruitment plan. Secondarily, the investigators intend to collect data to inform effect size estimates on outcomes to plan for an R01.

Interventions

  • Behavioral Cannabis Conversation Skills for Families (CCSF)
    The purpose of the intervention is to train family members in communication skills that may increase contemplation of change in their loved one with first episode psychosis to reduce cannabis use, decrease conflict surrounding these discussions, and provide skills to understand when and how to approach their loved one about cannabis use and encourage treatment. Because families report confusion from the mixed messages they receive about cannabis and also desire research-based information, CCSF w

Primary outcome measures

  • Cannabis and psychosis knowledge [Time frame: baseline, 3 month follow-up]
  • Caregiver Burden Index [Time frame: baseline, 3 month follow-up]
  • Family Attitudes Scale (FAS) [Time frame: baseline, 3 month follow-up]
  • Timeline Followback - Collateral version (TLFB-C) [Time frame: baseline, 3 month follow up]
  • Motivational Interviewing Treatment Integrity (MITI) [Time frame: baseline, post-treatment (6 week)]
Secondary outcome measures (1)
  • Client Satisfaction Questionnaire (CSQ-8) [Time frame: 3 month follow up]

Eligibility criteria

Inclusion criteria

  • aged 18 years or older,
  • has a loved one who is both in CSC treatment for FEP and has used cannabis in the past 30 days,
  • has regular contact with their loved one with FEP. It is assumed that YA-P will be aged 13-40 with schizophrenia spectrum disorder given criteria for CSC enrollment.

Exclusion criteria

  • Unable to read study materials and communicate feedback in English
  • Do not have access to Zoom

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • The University of Washington — Seattle

Identifiers

NCT: NCT06961877 · STUDY00022601 · 1R34MH133684-01A1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗